Context Therapeutics’ Post

Multi-omics inspection of clinical pd-1 resistant NSCLC reveals that Galectin-9 expressing tumor cells sustained the primary resistance of neoadjuvant anti-PD-1 therapy in NSCLC through galectin-9/TIM-3-mediated suppression of imcDC2 and CD8+ TRMs. https://lnkd.in/gxWT82MQ

INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors https://lnkd.in/e4GWSp96

Please read our paper just published in JITC. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. https://lnkd.in/eXwDBGZc  https://lnkd.in/ecqjqda3

Join our webinar on January 17th at noon to learn how Lisata Therapeutics is focusing on ways to target and penetrate solid tumors. https://hubs.la/Q02fwY5d0

#KeiretsuBacked Seneca Therapeutics, Inc. achieves another milestone with the publication of the TEM8 review article “TEM8 in Oncogenesis" in the Cells Journal. Read more about how it sheds light on TEM8's pivotal role in solid tumors: https://bit.ly/4agnbyy #SenecaTherapeutics #TEM8Research #OncogenesisInsights #CellsJournal #CancerResearch

#KeiretsuBacked Seneca Therapeutics, Inc. achieves another milestone with the publication of the TEM8 review article “TEM8 in Oncogenesis" in the Cells Journal. Read more about how it sheds light on TEM8's pivotal role in solid tumors: https://bit.ly/4agnbyy #SenecaTherapeutics #TEM8Research #OncogenesisInsights #CellsJournal #CancerResearch

Is cell-avidity tuning the solution for safe CAR-T therapy for solid tumors? 👀 The shortage of tumor-specific antigens is one of the major challenges in CAR-T therapy for solid tumors. Solid tumors are heterogenous in antigen expression which makes the identification of suitable target antigens essential in CAR-T therapy. 🔎 LUMICKS’s technology, the z-Movi Cell Avidity Analyser allows the assessment of cell binding strength and the tailoring of safer CAR-T therapies. 🖥️ Find out more in our article! ⬇️ https://lnkd.in/dxpyqK-q #CAR-Ttherapy #solidtumors #cellaviditytuning #cancerresearch #Immunotherapy #biotechinnovation #medicaltechnology

Cell therapy has the promise to cure multiple forms of cancer in the coming decades. It makes use of genetically modified immune cells that recognise, bind and kill the tumour cells. A huge challenge in developing these therapies is ensuring that the product only attacks the tumour cells and not the healthy cells of the patient. This is intrinsically hard for cancer cells since these were already able to evade the immune system and look pretty similar to healthy cells from the outside. To this extend the immune product needs to be “tuned” to only bind and recognise to tumor cells and not bind to healthy cells. This happens on the timescale of minutes and is exactly this what we can directly quantify with the LUMICKS Cell Avidity product. Exciting to see that the renowned institute Dana Farber (Yufei (Sophie) Wang) was able to avidity tune their product to improve the safety of their cell therapy. At LUMICKS we are humbled to be able to support such research that will impact human life. 

New #JITC article: rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors https://bit.ly/48P0Ztq NeoImmuneTech

Another big win for cell therapy! Adaptimmune has received U.S. FDA accelerated approval for TECELRA® (afamitresgene autoleucel), a novel engineered cell therapy for treating advanced synovial sarcoma in adults. This therapy, the first of its kind for solid tumors, targets patients who have specific HLA types and have previously undergone chemotherapy. Approval is based on overall response rate and duration of response from the SPEARHEAD-1 trial. TECELRA provides a new treatment option after more than a decade for synovial sarcoma patients. For more details, you can read the full release at the following link https://lnkd.in/gp68yd6U